|
WO2021076565A1
|
|
Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
|
|
US2020268723A1
|
|
Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator
|
|
US2020197381A1
|
|
Methods of Treating Cancer Comprising Administration of a Glucocorticoid Receptor Modulator and a Cancer Chemotherapy Agent
|
|
WO2020132469A1
|
|
Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators
|
|
WO2020132171A1
|
|
Methods for imaging and treatment of somatostatin-receptor positive tumors
|
|
US2020197373A1
|
|
Methods of Treating Cancer Comprising Administration of a Glucocorticoid Receptor Modulator and a Cancer Chemotherapy Agent
|
|
US2020197372A1
|
|
Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound
|
|
US2020147065A1
|
|
Methods for shrinking pituitary tumors
|
|
EP3590517A1
|
|
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
|
